Following the successful Medical and Life Sciences Translational Fund (MLSTF) launch event on the 29th November, the Translational Research Office (TRO) are pleased to announce that the MLSTF 2024 is NOW OPEN to applicants until the 5th February 2024.
MLSTF funds proof-of-concept projects at the earliest stages of translation, supporting preliminary work or feasibility studies to establish the viability of an approach. Projects are expected to last between 6 - 12 months in duration.
For 2024, the project-managed MLSTF fund has increased to £1.5M to ‘pump-prime’ the translation of novel therapeutics, devices, diagnostics and other therapeutic interventions (including ‘repurposing of existing therapies’) towards clinical testing. This year, following feedback from the previous call, MLSTF has undergone transformational changes to open the opportunity to a wider range of applicants and to increase the quality of applications received for the panel to review including:
1. An increase in funding volume per project from £75k to £85k 2. A dedicated route termed “Emerging Translational Innovators (ETI)” which provides an opportunity for early career researchers to leverage this fund as a stepping stone towards independently pursuing their translational research endeavours 3. A softened cap on the maximum number of applications from two to THREE per applicant (as PI, or Co-I) 4. Availability of dedicated funds to achieve clinical impact through clinical translation and human applications
Applications for MLSTF must be made in IRAMS. For general information regarding the TRO, please see the TRO website, and for more details on the MLSTF application process please refer to the MLSTF call text webpage.
| Date |
05/02/24 |
| Time |
10.00 am |
| Event type |
Funding |
| Application required |
Apply Here |
